OverviewSuggest Edit

Neuronetics is a medical device company. It develops non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. In addition, the Company provides NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation.
TypePublic
Founded2003
HQMalvern, PA, US
Websiteneurostar.com

Latest Updates

Employees (est.) (Dec 2019)235
Revenue (FY, 2020)$49.2 M(-21%)
Share Price (Jun 2021)$15.6(-2%)
Cybersecurity ratingCMore

Key People/Management at Neuronetics

Charles E. Larsen

Charles E. Larsen

Co-Founder
Mark A. Demitrack

Mark A. Demitrack

Chief Medical Officer
Kevin Bitterman

Kevin Bitterman

Director
Mary Hailey

Mary Hailey

VP of Health Policy and Government Relations
Show more

Neuronetics Office Locations

Neuronetics has an office in Malvern
Malvern, PA, US (HQ)
31 General Warren Blvd
Show all (1)

Neuronetics Financials and Metrics

Neuronetics Revenue

Embed Graph
View revenue for all periods
Neuronetics's revenue was reported to be $49.24 m in FY, 2020
USD

Revenue (Q1, 2021)

12.3m

Gross profit (Q1, 2021)

10.1m

Gross profit margin (Q1, 2021), %

81.9%

Net income (Q1, 2021)

(7.9m)

EBIT (Q1, 2021)

(6.9m)

Market capitalization (11-Jun-2021)

402.2m

Closing stock price (11-Jun-2021)

15.6

Cash (31-Mar-2021)

121.3m

EV

316.3m
Neuronetics's current market capitalization is $402.2 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

52.8m62.7m49.2m

Cost of goods sold

12.4m15.4m11.6m

Gross profit

40.3m47.3m37.7m

Gross profit Margin, %

76%75%77%
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

13.3m13.7m12.7m16.6m16.0m11.5m9.7m12.4m12.3m

Cost of goods sold

3.2m3.0m2.8m4.2m4.2m2.8m2.3m2.7m2.2m

Gross profit

10.0m10.7m9.9m12.4m11.8m8.7m7.4m9.8m10.1m

Gross profit Margin, %

76%78%78%75%74%76%76%79%82%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

104.6m75.7m49.0m

Accounts Receivable

5.6m6.6m7.2m

Prepaid Expenses

1.8m1.8m2.2m

Inventories

2.4m2.8m3.7m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

14.5m106.8m96.1m89.6m82.4m63.6m54.0m50.7m121.3m

Accounts Receivable

4.7m5.3m5.7m7.6m7.6m6.3m6.6m5.6m7.0m

Prepaid Expenses

4.3m2.1m1.6m1.1m2.0m1.8m1.1m2.7m2.2m

Inventories

2.4m2.6m2.4m2.6m2.9m2.9m3.3m3.8m5.4m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(24.1m)(29.0m)(27.5m)

Depreciation and Amortization

882.0k1.1m941.0k

Inventories

(435.0k)(306.0k)(945.0k)

Accounts Payable

606.0k299.0k(1.1m)
USDQ2, 2018

EV/EBIT

-88.1 x

EV/CFO

-34.4 x

Revenue/Employee

70.5k

Debt/Equity

-0.1 x

Debt/Assets

1.1 x

Financial Leverage

-0.1 x
Show all financial metrics

Neuronetics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

Neuronetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Neuronetics Online and Social Media Presence

Embed Graph

Neuronetics News and Updates

Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting

The market leader in transcranial magnetic stimulation will spotlight real-world clinical data on NeuroStar® Advanced Therapy for Mental Health The market leader in transcranial magnetic stimulation will spotlight real-world clinical data on NeuroStar® Advanced Therapy for Mental Health

Neuronetics to Present at The JMP Securities Life Sciences Conference

MALVERN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Su…

Neuronetics Names Todd Cushman as Vice President, Business Development

With this new appointment, the market leader in transcranial magnetic stimulation will continue expanding treatment access for patients with Major Depressive Disorder With this new appointment, the market leader in transcranial magnetic stimulation will continue expanding treatment access for patien…

Neuronetics to Present at the William Blair 41st Annual Growth Stock Conference

MALVERN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sul…

Neuronetics Reports First Quarter 2021 Financial and Operating Results

MALVERN, Pa., May 04, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial …

Neuronetics Employee Patient Advocates Honor Mental Health Awareness Month by Sharing Personal Depression Experiences

Employees who have found depression relief with NeuroStar Advanced Therapy for Mental Health use their voice to help others Employees who have found depression relief with NeuroStar Advanced Therapy for Mental Health use their voice to help others
Show more

Neuronetics Blogs

Neuronetics® Celebrates 100,000 Treatment Milestone for Southern California TMS Center

The market leader in transcranial magnetic stimulation therapy celebrates leading provider of NeuroStar Advanced Therapy for Mental Health MALVERN, Pa. , May 17, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results

MALVERN, Pa. , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today, in advance of the

Neuronetics Announces the Amendment of Credit Facility with Solar Capital Partners

Amendment provides Neuronetics with available and flexible funding options through 2022 MALVERN, Pa. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality

Neuronetics® Receives FDA Clearance for Three-Minute TouchStar™ Treatment Protocol

TouchStar theta burst protocol leverages NeuroStar® Advanced Therapy’s patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients MALVERN, Pa. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology

Neuronetics Reports Third Quarter 2020 Financial and Operating Results

MALVERN, Pa. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial

Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

MALVERN, Pa. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics , Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it
Show more

Neuronetics Frequently Asked Questions

  • When was Neuronetics founded?

    Neuronetics was founded in 2003.

  • Who are Neuronetics key executives?

    Neuronetics's key executives are Charles E. Larsen, Mark A. Demitrack and Kevin Bitterman.

  • How many employees does Neuronetics have?

    Neuronetics has 235 employees.

  • What is Neuronetics revenue?

    Latest Neuronetics annual revenue is $49.2 m.

  • What is Neuronetics revenue per employee?

    Latest Neuronetics revenue per employee is $209.5 k.

  • Who are Neuronetics competitors?

    Competitors of Neuronetics include Tombot, Elevations RTC and Salience TMS Neuro Solutions.

  • Where is Neuronetics headquarters?

    Neuronetics headquarters is located at 31 General Warren Blvd, Malvern.

  • Where are Neuronetics offices?

    Neuronetics has an office in Malvern.

  • How many offices does Neuronetics have?

    Neuronetics has 1 office.